Duration of mild acute SARS-CoV-2 infections with Omicron depending on previous vaccinations and infections – Using data of the German DigiHero cohort study from post-pandemic winters 2022/2023 and 2023/2024

IF 4.7 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health Pub Date : 2025-03-12 DOI:10.1016/j.jiph.2025.102746

Nadine Glaser , Sophie Diexer , Bianca Klee , Janka Massag , Laura R. Pfrommer , Oliver Purschke , Mascha Binder , Thomas Frese , Matthias Girndt , Jessica I. Hoell , Irene Moor , Jonas Rosendahl , Michael Gekle , Daniel Sedding , Cornelia Gottschick , Rafael Mikolajczyk

{"title":"Duration of mild acute SARS-CoV-2 infections with Omicron depending on previous vaccinations and infections – Using data of the German DigiHero cohort study from post-pandemic winters 2022/2023 and 2023/2024","authors":"Nadine Glaser , Sophie Diexer , Bianca Klee , Janka Massag , Laura R. Pfrommer , Oliver Purschke , Mascha Binder , Thomas Frese , Matthias Girndt , Jessica I. Hoell , Irene Moor , Jonas Rosendahl , Michael Gekle , Daniel Sedding , Cornelia Gottschick , Rafael Mikolajczyk","doi":"10.1016/j.jiph.2025.102746","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Protection against severe course of SARS-CoV-2 infection after COVID-19 vaccination or infection was extensively studied. It is unknown whether this effect also translates into shortened duration of mild infections. We assessed the duration of symptoms depending on vaccination status and previous SARS-CoV-2 infections among individuals with a mild course of infection.</div></div><div><h3>Methods</h3><div>For two post-pandemic winters (2022/2023 and 2023/2024), in total 13,615 participants of the German DigiHero study reported their SARS-CoV-2 infections from September to March. Via negative binomial regression adjusting for sociodemographic factors, we studied the association of infection duration (days with symptoms and in bed) with number of vaccinations, prior SARS-CoV-2 infections, and time since last vaccination/and infection.</div></div><div><h3>Results</h3><div>We noted no major differences in infection duration depending on the number of vaccinations and time since last infection for short mild infections (≤21 days with symptoms). Per 6 months since the last vaccination, symptom duration and days spent in bed increased by 2 % and 4 %. The risk of long mild SARS-CoV-2 infections (>21 days with symptoms) was higher for individuals with no prior SARS-CoV-2 infection (Odds Ratio: 1.98; 95 % confidence interval [1.43; 2.76]), but not for vaccinations (OR: 0.98; 95 % CI [0.74; 1.33]).</div></div><div><h3>Conclusions</h3><div>There was no indication of reduced duration of symptoms during short mild infections depending on the number of vaccinations and time since the last SARS-CoV-2 vaccination or infection. A prior SARS-CoV-2 infection was protective against prolonged disease in mild SARS-CoV-2 infections.</div></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":"18 6","pages":"Article 102746"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Public Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876034125000954","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Protection against severe course of SARS-CoV-2 infection after COVID-19 vaccination or infection was extensively studied. It is unknown whether this effect also translates into shortened duration of mild infections. We assessed the duration of symptoms depending on vaccination status and previous SARS-CoV-2 infections among individuals with a mild course of infection.

Methods

For two post-pandemic winters (2022/2023 and 2023/2024), in total 13,615 participants of the German DigiHero study reported their SARS-CoV-2 infections from September to March. Via negative binomial regression adjusting for sociodemographic factors, we studied the association of infection duration (days with symptoms and in bed) with number of vaccinations, prior SARS-CoV-2 infections, and time since last vaccination/and infection.

Results

We noted no major differences in infection duration depending on the number of vaccinations and time since last infection for short mild infections (≤21 days with symptoms). Per 6 months since the last vaccination, symptom duration and days spent in bed increased by 2 % and 4 %. The risk of long mild SARS-CoV-2 infections (>21 days with symptoms) was higher for individuals with no prior SARS-CoV-2 infection (Odds Ratio: 1.98; 95 % confidence interval [1.43; 2.76]), but not for vaccinations (OR: 0.98; 95 % CI [0.74; 1.33]).

Conclusions

There was no indication of reduced duration of symptoms during short mild infections depending on the number of vaccinations and time since the last SARS-CoV-2 vaccination or infection. A prior SARS-CoV-2 infection was protective against prolonged disease in mild SARS-CoV-2 infections.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Public Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -INFECTIOUS DISEASES

CiteScore

13.10

自引率

1.50%

发文量

203

审稿时长

96 days

期刊介绍： The Journal of Infection and Public Health, first official journal of the Saudi Arabian Ministry of National Guard Health Affairs, King Saud Bin Abdulaziz University for Health Sciences and the Saudi Association for Public Health, aims to be the foremost scientific, peer-reviewed journal encompassing infection prevention and control, microbiology, infectious diseases, public health and the application of healthcare epidemiology to the evaluation of health outcomes. The point of view of the journal is that infection and public health are closely intertwined and that advances in one area will have positive consequences on the other. The journal will be useful to all health professionals who are partners in the management of patients with communicable diseases, keeping them up to date. The journal is proud to have an international and diverse editorial board that will assist and facilitate the publication of articles that reflect a global view on infection control and public health, as well as emphasizing our focus on supporting the needs of public health practitioners. It is our aim to improve healthcare by reducing risk of infection and related adverse outcomes by critical review, selection, and dissemination of new and relevant information in the field of infection control, public health and infectious diseases in all healthcare settings and the community.